State Street Corp Buys 21,729 Shares of Enfusion, Inc. (NYSE:ENFN)

State Street Corp increased its stake in shares of Enfusion, Inc. (NYSE:ENFN) by 2.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 952,895 shares of the company’s stock after purchasing an additional 21,729 shares during the quarter. State Street Corp owned about 0.74% of Enfusion worth $9,043,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Arizona State Retirement System acquired a new stake in shares of Enfusion in the 2nd quarter valued at $86,000. Harbor Capital Advisors Inc. boosted its holdings in Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after acquiring an additional 1,315 shares during the last quarter. Belvedere Trading LLC acquired a new stake in Enfusion in the third quarter worth about $114,000. Paloma Partners Management Co acquired a new stake in Enfusion in the third quarter worth about $157,000. Finally, The Manufacturers Life Insurance Company raised its holdings in Enfusion by 27.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock worth $167,000 after purchasing an additional 4,239 shares during the last quarter. Institutional investors and hedge funds own 81.05% of the company’s stock.

Enfusion Stock Up 1.0 %

Shares of ENFN stock opened at $10.69 on Friday. Enfusion, Inc. has a 12-month low of $7.52 and a 12-month high of $11.38. The firm has a fifty day moving average of $9.80 and a 200-day moving average of $9.04. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of 267.32, a price-to-earnings-growth ratio of 3.98 and a beta of 0.97.

Insider Transactions at Enfusion

In related news, CFO Bradley Herring sold 24,443 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $10.61, for a total transaction of $259,340.23. Following the completion of the transaction, the chief financial officer now directly owns 270,503 shares of the company’s stock, valued at approximately $2,870,036.83. This represents a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Neal Pawar sold 21,801 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the sale, the chief operating officer now directly owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 46,918 shares of company stock valued at $484,037 over the last quarter. Corporate insiders own 36.44% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Piper Sandler raised their target price on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday. Stifel Nicolaus lifted their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.25.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.